Drugs / G1T28-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02243150 | Sep 2014 → Feb 2015 | — | G1 Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G1T28-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243150 ↗ |
| Action | Inhibit | “CDK 4/6 Inhibitor” NCT02243150 ↗ |
| Route | Intravenous | “administered in 50mL of 5% dextrose by IV infusion” NCT02243150 ↗ |